CLL Clinical Trials CLL is not a solved problem, but we do have excellent treatments. It was only through clinical trials that the safety and efficacy of existing therapies was proven, and the
Clinicaltrials.gov is a US-based website that requires companies and investigators to post information about clinical trials in a public forum. All US trials should be posted within about 3 weeks of
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
CLL Society has actively promoted equitable access in CLL trials and researched what factors determine the patient’s choice to enroll.
NX-5948 is a novel type of drug, classified as a BTK degrader, and it has shown promising early clinical data.
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
Disparities persist as Blacks, Hispanics, and females are underrepresented in clinical trials for CLL and other blood cancers.
Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.
Preclinical research shows that LP-168 inhibits BTK in CLL cells regardless of whether resistance mutations exist.
